Phase III clinical trial - Appareil pulmonaire

MERU (M16-298)
Appareil pulmonaire
Ouvert depuis le: 11.13.2019
Site: Paris
Public cible
Adulte
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU).
Description de l'essai

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.